NCT05111080

Brief Summary

  • Detection of chromosome 10q23 deletion including PTEN locus in breast cancer patients.
  • Correlation between PTEN deletion and clinicopathological characteristics in breast cancer patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2021

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2021

Completed
5 days until next milestone

Study Start

First participant enrolled

November 1, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 8, 2021

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2025

Completed
Last Updated

November 8, 2021

Status Verified

October 1, 2021

Enrollment Period

3.2 years

First QC Date

October 27, 2021

Last Update Submit

October 27, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Detection of chromosome 10q23 deletion including PTEN locus in breast cancer patients.

    Correlation between PTEN deletion and clinicopathological characteristics in breast cancer patients.

    baseline

Eligibility Criteria

Age20 Years+
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All stages of female patients with breast cancer. Median age was 63 (range 20-100) years

You may qualify if:

  • all stages of breast cancer in females.

You may not qualify if:

  • breast cancer in males.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Young PA, Kaiser II. Aminoacylation of Escherichia coli cysteine tRNA by selenocysteine. Arch Biochem Biophys. 1975 Dec;171(2):483-9. doi: 10.1016/0003-9861(75)90057-0. No abstract available.

    PMID: 963BACKGROUND

Central Study Contacts

Fatma Refaat Ibrahim, resident doctor

CONTACT

Abeer Mostafa Darwish, Assistant Professor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

October 27, 2021

First Posted

November 8, 2021

Study Start

November 1, 2021

Primary Completion

December 30, 2024

Study Completion

January 30, 2025

Last Updated

November 8, 2021

Record last verified: 2021-10